Nemocnica AGEL Zvolen a.s.

The Gastroenterology outpatient clinic at Nemocnica AGEL Zvolen a.s. conducts research focused on heart failure, evaluating new drug combinations such as vicadrostat and empagliflozin to improve survival and reduce hospitalizations.

• Combination therapy with vicadrostat and empagliflozin
• Assessment of cardiovascular mortality and heart failure outcomes
• Exploration of treatment effects in patients with reduced left ventricular ejection fraction

These studies aim to advance treatment options for patients with compromised heart function and provide evidence for better clinical guidelines.

Investigators are studying moderate to severe ulcerative colitis, testing long‑acting antibodies to induce remission and heal intestinal tissue.

• Evaluation of histologic disease activity after 12 weeks
• Measurement of clinical remission rates
• Combination versus monotherapy approaches

The goal is to offer more effective therapies for patients struggling with chronic inflammation of the colon.

Research also targets anemia in chronic kidney disease patients on dialysis, comparing erythropoiesis‑stimulating agents such as efepoetin alfa and darbepoetin alfa to maintain stable hemoglobin levels.

• Non‑inferiority assessment of efepoetin alfa vs. darbepoetin alfa
• Monitoring of hemoglobin control in hemodialysis settings
• Safety and tolerability profiling of treatment options

Findings aim to improve quality of life for individuals receiving regular dialysis by optimizing anemia management.